

Monitoring Report: Respiratory Viruses - December 2023 Data

Samuel Gratzl, PhD

Brianna M Goodwin Cartwright, MS

Patricia J Rodriguez, PhD, MPH

Charlotte Baker, DrPH, MPH, CPH

Nicholas L Stucky, MD, PhD

Affiliations: All authors are affiliated with Truveta, Inc.

Corresponding author:

Dr Nicholas Stucky

Truveta, Inc

1745 114th Ave SE, Bellevue, WA 98004

Email: nicholass@truveta.com

Abstract

Background: Few sources regularly monitor hospitalizations associated with respiratory viruses. This study provides current hospitalization trends associated with six common respiratory viruses: COVID-19, influenza, human metapneumovirus (HMPV), parainfluenza virus, respiratory syncytial virus (RSV), and rhinovirus.

Objective: This study aims to supplement the surveillance data provided by the CDC by describing trends overall and for each respiratory virus. This study also provides valuable insight into two at-risk populations: infants and children (age 0-4) and older adults (age 65 and over).

Methods: Using a subset of real-world electronic health record (EHR) data from Truveta, a growing collective of health systems that provide more than 18% of all daily clinical care in the USA consortium of US healthcare systems, we identified people who were hospitalized between October 01, 2019 and December 31, 2023. We identified people who tested positive for any of the six respiratory virus within 14 days of the hospitalization. We report weekly trends in the rate of hospitalizations associated with each virus per all hospitalizations for the overall population and the two high-risk sub populations, infants and children and older adults.


Results: We included 502,484 hospitalizations of 471,401 unique patients who tested positive for a respiratory virus between October 01, 2019 and December 31, 2023.

Overall, the rate of hospitalizations associated with respiratory viruses continue to increase through the end of December 2023 (92.8% increase since November 2023). The largest increases over the past month have been seen in influenza- (251.7% increase), HMPV- (115.0% increase), and COVID-associated (88.6% increase) hospitalizations. For infants and children, RSV accounted for the most respiratory virus-associated hospitalizations, despite decreases throughout December 2023. In this population, COVID-associated hospitalizations had the biggest increase in the last month. For the older adult population, respiratory virus-associated hospitalizations increased to 10.3% per all hospitalizations. COVID remained the largest contributor; 5.3% of all hospitalizations were associated with COVID in the older adult population.

Discussion: Respiratory virus-associated hospitalizations continued to increase overall, including for the two high risk populations we studied. RSV-associated hospitalizations continue to be the main contributor to illness in infants and children, while COVID-associated hospitalizations are the largest contributor for the older adult population. We will continue to monitor trends in all respiratory viruses.

Trends in Surveillance


Overall population



| | Overall | COVID | influenza | HMPV | parainfluenza virus | RSV | rhinovirus |
|--------------------------------|---------|---------|-----------|----------|---------------------|---------|------------|
| November 27, 2023 | 4.01% | 1.76% | 0.84% | 0.05% | 0.10% | 0.81% | 0.58% |
| December 25, 2023 | 7.73% | 3.31% | 2.96% | 0.10% | 0.09% | 0.93% | 0.61% |
| Change (percentage) | +92.83% | +88.62% | +251.72% | +115.03% | -9.63% | +14.86% | +6.86% |
| Difference (percentage points) | +3.72% | +1.56% | +2.12% | +0.05% | -0.01% | +0.12% | +0.04% |

Overall, the rate of hospitalizations associated with respiratory viruses continue to increase through the end of December 2023 (92.8% increase since November 2023). Specifically, COVID- (88.6%), influenza- (251.7%), and HMPV- (115.0%) associated hospitalization trends increased. COVID and influenza-associated hospitalizations are at 3.3% and 3.0% of all hospitalizations, respectively. Other viruses are each below 1% of hospitalizations. Nevertheless, at the end of December 2023, respiratory virus-associated hospitalizations accounted for 7.7% of all hospitalizations.


Infants and children (age 0-4)



| | Overall | COVID | influenza | HMPV | parainfluenza virus | RSV | rhinovirus |
|--------------------------------|---------|----------|-----------|-------|---------------------|---------|------------|
| November 27, 2023 | 4.59% | 0.24% | 0.51% | n/a | n/a | 3.05% | 1.19% |
| December 25, 2023 | 5.08% | 0.69% | 0.77% | 0.29% | n/a | 2.29% | 1.66% |
| Change (percentage) | +10.53% | +183.40% | +52.48% | | | -24.70% | +39.51% |
| Difference (percentage points) | +0.48% | +0.45% | +0.27% | | | -0.75% | +0.47% |

For the population between 0-4 years old, in December 2023, RSV accounted for the most respiratory virus-associated hospitalizations, despite decreasing rates since November 2023 (24.7% decrease). COVID- (183.5% increase), influenza- (52.5% increase), and rhino-associated (39.5% increase) hospitalizations are increasing in this population. In this age group, 5.1% of all hospitalizations were associated with respiratory viruses in December 2023, a 10.5% increase from November 2023.

Older adults (age 65 and over)



| | Overall | COVID | influenza | HMPV | parainfluenza virus | RSV | rhinovirus |
|--------------------------------|---------|---------|-----------|---------|---------------------|---------|------------|
| November 27, 2023 | 5.31% | 2.90% | 0.91% | 0.07% | 0.10% | 0.84% | 0.57% |
| December 25, 2023 | 10.29% | 5.33% | 3.33% | 0.12% | 0.09% | 1.11% | 0.56% |
| Change (percentage) | +93.71% | +83.52% | +267.84% | +76.00% | -12.54% | +32.53% | -1.82% |
| Difference (percentage points) | +4.98% | +2.42% | +2.43% | +0.05% | -0.01% | +0.27% | -0.01% |

In the older adults population (individuals over 65 years of age), there was a 93.7% increase in hospitalizations associated with respiratory viruses; 10.3% of all hospitalizations are associated with a respiratory virus. Influenza-associated hospitalizations had the largest percent increase between November and December 2023 (267.8%). COVID-associated hospitalizations continue to make up the largest percentage of hospitalizations in this age group (5.3% in December).

Introduction

COVID, influenza, and RSV account for a large proportion of hospitalizations related to respiratory illnesses in the United States. To provide a more complete understanding of hospitalizations related to respiratory viruses, we have also included other viruses known to cause respiratory illness such as human metapneumovirus (HMPV), parainfluenza, and rhinovirus. Each of these viruses can lead to hospitalization and death especially in vulnerable populations, such as infants, children, and older adults (Pastula et al., 2017; Shi et al., 2017, Centers for Disease Control and Prevention 2023a, Smits et al., 2023). Representative and timely data to proactively monitor infections are scarce.

Respiratory viruses are also a major source of infection and hospitalizations in older adults (defined here as patients 65 years of age or older). Incidence has been estimated between 3-10% annually for RSV in older adults (Boyce et al., 2000) and 8-10% for influenza in adults (Tokars et al., 2018). Often, as is the case with influenza, older adults are at higher risk for hospitalization and death than other age groups (Czaja et al. 2019). There are comorbidities that are associated with increased hospitalization risk for older adults, such as congestive heart failure and chronic lung disease (Lee et al., 2013). Further, asthma, COPD, and congestive heart failure can exacerbate respiratory virus infections. Here we report counts for a selection of high-risk medical conditions such as chronic lung diseases and asthma.

Incidence rates in infants and children (defined here as individuals less than five years of age) with respiratory virus infections are higher than other age groups, except adults 65 and older (Centers for Disease Control and Prevention, 2023c; Centers for Disease Control and Prevention, 2023d). In the future, we plan to include high-risk comorbid states, such as congenital heart disease, preterm birth, and cystic fibrosis (Committee on Infectious Diseases and Bronchiolitis Guidelines Committee et al., 2014).

It is important for public health experts and clinical providers to understand the trends in these infections to inform decisions about public health, clinical care, and public policy. Connecting population-level trends with granular clinical information available in Truveta Studio can be very useful to more deeply understand which cohorts are most impacted.

This report is intended to supplement the surveillance data provided by the CDC (Centers for Disease Control and Prevention, 2023b). This report includes additional independent data and clinical detail that is not captured in other reports.

Methods

Data

We evaluated respiratory virus-associated hospitalization trends of six common respiratory viruses: COVID-19, influenza, human metapneumovirus (HMPV), parainfluenza virus, respiratory syncytial virus (RSV), and rhinovirus between October 01, 2019 and December 31, 2023 using a subset of Truveta Data. Truveta provides access to continuously updated, linked, and de-identified electronic health record (EHR) from a collective of US health care systems that provide 18% of all daily clinical care in the US, including structured information on demographics, encounters, diagnoses, vital signs (e.g., weight, BMI, blood pressure), medication requests (prescriptions), medication administration, laboratory and diagnostic tests and results (e.g., COVID tests and values), and procedures. Updated EHR data are provided daily to Truveta by constituent health care systems. The data used in this study was provided on January 15, 2024 and included de-identified patient care data primarily located across ten states: Texas, Virginia, New York, Florida, California, Michigan, Washington, North Carolina, Wisconsin, and Louisiana.

Population

We identified hospitalized patients who tested positive for one of the selected respiratory viruses within 14 days before or during the hospitalization. Positive lab results were identified using LOINC codes. Every respiratory virus-associated hospitalization has been grouped such that every hospitalization within 90 days is considered to be the same infection and thus only counted once. To align with seasonality in respiratory transmission, time periods include October 1st through September 30th of the following year.

Hospitalization rate analysis

Characteristics of respiratory virus-associated hospitalized patients were summarized, including demographics and comorbidities by respiratory virus season. Characteristics are provided for the overall population, individual viruses, and two at-risk sub populations: infants and children (age 0-4) and older adults (age 65 and over).

Respiratory virus-associated hospitalizations rates were summarized over time by virus. The hospitalization rate was calculated weekly as the number of patients with a respiratory virus associated hospitalization divided by the number of patients with a hospital admission in that week. Patients were included in this calculation on the first

day of their hospitalization. If their stay was greater than one day, they were not counted on subsequent dates.

Given the unadjusted nature of the data, the rates do not account for undertesting and other variability that exists across patient groups, providers, and systems. For further limitations, see the section below.

Results

Overall population

Our study population consists of 502,484 hospitalizations of 471,401 unique patients (Table 1).

Table 1: Patient characteristics by season.

| | 2019/2020 | 2020/2021 | 2021/2022 | 2022/2023 | 2023/2024 | Overall |
|---------------------------|---------------------|----------------------|----------------------|---------------------|---------------------|----------------------|
| N | 72,744 (100.00%) | 149,376 (100.00%) | 136,913 (100.00%) | 88,226 (100.00%) | 24,142 (100.00%) | 471,401 (100.00%) |
| Age Group | | | | | | |
| < 6 months | 1,352 (1.86%) | 1,299 (0.87%) | 2,196 (1.60%) | 2,391 (2.71%) | 934 (3.87%) | 8,172 (1.73%) |
| 6 - <12 months | 622 (0.86%) | 435 (0.29%) | 888 (0.65%) | 1,125 (1.28%) | 402 (1.67%) | 3,472 (0.74%) |
| 1 - <2 years | 771 (1.06%) | 716 (0.48%) | 1,355 (0.99%) | 1,577 (1.79%) | 536 (2.22%) | 4,955 (1.05%) |
| 2 - 4 years | 960 (1.32%) | 847 (0.57%) | 1,936 (1.41%) | 2,364 (2.68%) | 649 (2.69%) | 6,756 (1.43%) |
| 5 - 17 years | 1,083 (1.49%) | 1,791 (1.20%) | 2,687 (1.96%) | 2,877 (3.26%) | 823 (3.41%) | 9,261 (1.96%) |
| 18 - 49 years | 17,090 (23.49%) | 38,802 (25.98%) | 32,289 (23.58%) | 13,592 (15.41%) | 3,389 (14.04%) | 105,162 (22.31%) |
| 50 - 64 years | 18,478 (25.40%) | 38,096 (25.50%) | 28,098 (20.52%) | 14,249 (16.15%) | 3,932 (16.29%) | 102,853 (21.82%) |
| 65 - 74 years | 13,960 (19.19%) | 29,868 (20.00%) | 26,560 (19.40%) | 17,094 (19.38%) | 4,563 (18.90%) | 92,045 (19.53%) |
| 75 - 84 years | 11,692 (16.07%) | 24,347 (16.30%) | 25,386 (18.54%) | 19,599 (22.21%) | 5,252 (21.75%) | 86,276 (18.30%) |
| 85+ years | 6,736 (9.26%) | 13,175 (8.82%) | 15,518 (11.33%) | 13,358 (15.14%) | 3,662 (15.17%) | 52,449 (11.13%) |
| Sex | | | | | | |
| Female | 36,636 (50.36%) | 74,708 (50.01%) | 72,284 (52.80%) | 46,839 (53.09%) | 12,789 (52.97%) | 243,256 (51.60%) |
| Male | 35,849 (49.28%) | 74,083 (49.59%) | 64,235 (46.92%) | 41,160 (46.65%) | 11,279 (46.72%) | 226,606 (48.07%) |
| Other | n/a | n/a | n/a | n/a | n/a | n/a |
| Unknown | 257 (0.35%) | 580 (0.39%) | 384 (0.28%) | 225 (0.26%) | 73 (0.30%) | 1,534 (0.33%) |
| Race | | | | | | |
| White | 37,601 (51.69%) | 93,619 (62.67%) | 91,196 (66.61%) | 57,112 (64.73%) | 15,528 (64.32%) | 295,056 (62.59%) |
| Black or African American | 14,347 (19.72%) | 21,921 (14.68%) | 18,900 (13.80%) | 11,163 (12.65%) | 3,130 (12.96%) | 69,461 (14.74%) |

| | | | | | | |
|---|-----------------|------------------|------------------|-----------------|-----------------|------------------|
| Asian | 2,577 (3.54%) | 3,823 (2.56%) | 3,479 (2.54%) | 3,132 (3.55%) | 805 (3.33%) | 13,816 (2.93%) |
| Native Hawaiian or Other Pacific Islander | 148 (0.20%) | 228 (0.15%) | 208 (0.15%) | 121 (0.14%) | 31 (0.13%) | 736 (0.16%) |
| American Indian or Alaska Native | 244 (0.34%) | 548 (0.37%) | 599 (0.44%) | 452 (0.51%) | 104 (0.43%) | 1,947 (0.41%) |
| Other Race | 12,358 (16.99%) | 18,984 (12.71%) | 14,047 (10.26%) | 9,625 (10.91%) | 2,613 (10.82%) | 57,627 (12.22%) |
| Declined to answer | 358 (0.49%) | 655 (0.44%) | 646 (0.47%) | 444 (0.50%) | 161 (0.67%) | 2,264 (0.48%) |
| Unknown | 5,111 (7.03%) | 9,598 (6.43%) | 7,838 (5.72%) | 6,177 (7.00%) | 1,770 (7.33%) | 30,494 (6.47%) |
| Ethnicity | | | | | | |
| Hispanic or Latino | 13,515 (18.58%) | 22,706 (15.20%) | 17,188 (12.55%) | 11,716 (13.28%) | 3,245 (13.44%) | 68,370 (14.50%) |
| Not Hispanic or Latino | 50,710 (69.71%) | 110,816 (74.19%) | 108,967 (79.59%) | 70,535 (79.95%) | 19,325 (80.05%) | 360,353 (76.44%) |
| Declined to answer | 345 (0.47%) | 720 (0.48%) | 675 (0.49%) | 462 (0.52%) | 139 (0.58%) | 2,341 (0.50%) |
| Unknown | 8,174 (11.24%) | 15,134 (10.13%) | 10,083 (7.36%) | 5,513 (6.25%) | 1,433 (5.94%) | 40,337 (8.56%) |
| Virus | | | | | | |
| COVID | 48,356 (66.47%) | 142,215 (95.21%) | 120,840 (88.26%) | 53,299 (60.41%) | 11,380 (47.14%) | 376,090 (79.78%) |
| HMPV | 1,928 (2.65%) | 126 (0.08%) | 1,791 (1.31%) | 3,374 (3.82%) | 267 (1.11%) | 7,486 (1.59%) |
| RSV | 3,911 (5.38%) | 1,429 (0.96%) | 2,989 (2.18%) | 5,095 (5.77%) | 3,411 (14.13%) | 16,835 (3.57%) |
| influenza | 11,722 (16.11%) | 155 (0.10%) | 3,119 (2.28%) | 11,926 (13.52%) | 4,828 (20.00%) | 31,750 (6.74%) |
| parainfluenza virus | 925 (1.27%) | 882 (0.59%) | 1,589 (1.16%) | 3,054 (3.46%) | 544 (2.25%) | 6,994 (1.48%) |
| rhinovirus | 5,902 (8.11%) | 4,569 (3.06%) | 6,585 (4.81%) | 11,478 (13.01%) | 3,712 (15.38%) | 32,246 (6.84%) |
| Comorbidity | | | | | | |
| Asthma | 6,252 (8.59%) | 10,149 (6.79%) | 11,887 (8.68%) | 10,058 (11.40%) | 3,086 (12.78%) | 41,432 (8.79%) |
| Chronic Lung Disease | 4,169 (5.73%) | 7,182 (4.81%) | 7,542 (5.51%) | 6,190 (7.02%) | 1,931 (8.00%) | 27,014 (5.73%) |
| Chronic Obstructive Pulmonary Disease | 8,144 (11.20%) | 13,992 (9.37%) | 17,270 (12.61%) | 13,840 (15.69%) | 3,968 (16.44%) | 57,214 (12.14%) |

Hospitalization rate over time

The rate of respiratory virus-associated hospitalizations compared to all hospitalizations is shown in Figure 1. Figure 2 shows the same data stacked to represent the combined impact of the viruses.

Figure 1: Rate of weekly respiratory virus-associated hospitalizations compared to all hospital admissions since October 2019





Figure 2: Cumulative rate of weekly respiratory virus-associated hospitalizations compared to all hospital admissions since October 2019



COVID-19

Our COVID study population consists of 388,864 hospitalizations of 376,090 unique patients (Table 2).

Table 2: COVID patient characteristics by season.

| | 2019/2020 | 2020/2021 | 2021/2022 | 2022/2023 | 2023/2024 | Overall |
|----------------|---------------------|----------------------|----------------------|---------------------|---------------------|----------------------|
| N | 48,356 (100.00%) | 142,215 (100.00%) | 120,840 (100.00%) | 53,299 (100.00%) | 11,380 (100.00%) | 376,090 (100.00%) |
| Age Group | | | | | | |
| < 6 months | 81 (0.17%) | 550 (0.39%) | 939 (0.78%) | 360 (0.68%) | 75 (0.66%) | 2,005 (0.53%) |
| 6 - <12 months | 14 (0.03%) | 89 (0.06%) | 213 (0.18%) | 142 (0.27%) | 27 (0.24%) | 485 (0.13%) |
| 1 - <2 years | 17 (0.04%) | 140 (0.10%) | 256 (0.21%) | 112 (0.21%) | 29 (0.25%) | 554 (0.15%) |
| 2 - 4 years | 23 (0.05%) | 171 (0.12%) | 345 (0.29%) | 145 (0.27%) | 20 (0.18%) | 704 (0.19%) |
| 5 - 17 years | 240 (0.50%) | 1,123 (0.79%) | 1,358 (1.12%) | 451 (0.85%) | 65 (0.57%) | 3,237 (0.86%) |
| 18 - 49 years | 12,934 (26.75%) | 37,546 (26.40%) | 29,949 (24.78%) | 8,047 (15.10%) | 1,267 (11.13%) | 89,743 (23.86%) |
| 50 - 64 years | 13,401 (27.71%) | 37,085 (26.08%) | 25,819 (21.37%) | 8,620 (16.17%) | 1,642 (14.43%) | 86,567 (23.02%) |
| 65 - 74 years | 9,611 (19.88%) | 29,052 (20.43%) | 24,315 (20.12%) | 11,301 (21.20%) | 2,415 (21.22%) | 76,694 (20.39%) |
| 75 - 84 years | 7,806 (16.14%) | 23,679 (16.65%) | 23,362 (19.33%) | 14,093 (26.44%) | 3,339 (29.34%) | 72,279 (19.22%) |
| 85+ years | 4,229 (8.75%) | 12,780 (8.99%) | 14,284 (11.82%) | 10,028 (18.81%) | 2,501 (21.98%) | 43,822 (11.65%) |
| Sex | | | | | | |
| Female | 23,547 (48.70%) | 71,023 (49.94%) | 63,916 (52.89%) | 28,032 (52.59%) | 5,905 (51.89%) | 192,423 (51.16%) |
| Male | 24,635 (50.95%) | 70,633 (49.67%) | 56,555 (46.80%) | 25,134 (47.16%) | 5,442 (47.82%) | 182,399 (48.50%) |
| Other | n/a | n/a | n/a | n/a | n/a | n/a |
| Unknown | 172 (0.36%) | 554 (0.39%) | 360 (0.30%) | 131 (0.25%) | 32 (0.28%) | 1,263 (0.34%) |
| Race | | | | | | |
| White | 22,339 (46.20%) | 89,659 (63.04%) | 81,804 (67.70%) | 36,316 (68.14%) | 8,136 (71.49%) | 238,254 (63.35%) |

| | | | | | | |
|---|-----------------|------------------|-----------------|-----------------|----------------|------------------|
| Black or African American | 10,522 (21.76%) | 20,704 (14.56%) | 16,514 (13.67%) | 6,205 (11.64%) | 1,097 (9.64%) | 55,042 (14.64%) |
| Asian | 1,711 (3.54%) | 3,545 (2.49%) | 2,804 (2.32%) | 1,666 (3.13%) | 344 (3.02%) | 10,070 (2.68%) |
| Native Hawaiian or Other Pacific Islander | 100 (0.21%) | 217 (0.15%) | 170 (0.14%) | 59 (0.11%) | n/a | 554 (0.15%) |
| American Indian or Alaska Native | 131 (0.27%) | 508 (0.36%) | 522 (0.43%) | 248 (0.47%) | 55 (0.48%) | 1,464 (0.39%) |
| Other Race | 9,509 (19.66%) | 17,772 (12.50%) | 11,749 (9.72%) | 5,012 (9.40%) | 869 (7.64%) | 44,911 (11.94%) |
| Declined to answer | 269 (0.56%) | 636 (0.45%) | 546 (0.45%) | 247 (0.46%) | 57 (0.50%) | 1,755 (0.47%) |
| Unknown | 3,775 (7.81%) | 9,174 (6.45%) | 6,731 (5.57%) | 3,546 (6.65%) | 814 (7.15%) | 24,040 (6.39%) |
| Ethnicity | | | | | | |
| Hispanic or Latino | 10,429 (21.57%) | 21,521 (15.13%) | 14,672 (12.14%) | 5,977 (11.21%) | 1,062 (9.33%) | 53,661 (14.27%) |
| Not Hispanic or Latino | 31,533 (65.21%) | 105,384 (74.10%) | 96,502 (79.86%) | 43,555 (81.72%) | 9,594 (84.31%) | 286,568 (76.20%) |
| Declined to answer | 254 (0.53%) | 697 (0.49%) | 585 (0.48%) | 277 (0.52%) | 62 (0.54%) | 1,875 (0.50%) |
| Unknown | 6,140 (12.70%) | 14,613 (10.28%) | 9,081 (7.51%) | 3,490 (6.55%) | 662 (5.82%) | 33,986 (9.04%) |
| Comorbidity | | | | | | |
| Asthma | 2,812 (5.82%) | 9,135 (6.42%) | 9,484 (7.85%) | 4,769 (8.95%) | 1,203 (10.57%) | 27,403 (7.29%) |
| Chronic Lung Disease | 1,993 (4.12%) | 6,692 (4.71%) | 6,329 (5.24%) | 3,447 (6.47%) | 966 (8.49%) | 19,427 (5.17%) |
| Chronic Obstructive Pulmonary Disease | 3,472 (7.18%) | 13,053 (9.18%) | 14,849 (12.29%) | 8,007 (15.02%) | 1,971 (17.32%) | 41,352 (11.00%) |

Hospitalization rate over time

The rate of COVID-associated hospitalization is shown in Figure 3. Figure 4 shows seasonal trends.

Figure 3: Rate of weekly COVID-associated hospitalizations compared to all hospital admissions since October 2019





Figure 4: Rate of weekly COVID-associated hospitalizations compared to all hospital admissions by season



Influenza

Our influenza study population consists of 35,268 hospitalizations of 31,750 unique patients (Table 3).

Table 3: Influenza patient characteristics by season.

| | 2019/2020 | 2020/2021 | 2021/2022 | 2022/2023 | 2023/2024 | Overall |
|---|------------------|---------------|-----------------|------------------|-----------------|------------------|
| N | 11,722 (100.00%) | 155 (100.00%) | 3,119 (100.00%) | 11,926 (100.00%) | 4,828 (100.00%) | 31,750 (100.00%) |
| Age Group | | | | | | |
| < 6 months | 129 (1.10%) | n/a | 15 (0.48%) | 52 (0.44%) | 23 (0.48%) | 219 (0.69%) |
| 6 - <12 months | 81 (0.69%) | n/a | 12 (0.38%) | 59 (0.49%) | 17 (0.35%) | 169 (0.53%) |
| 1 - <2 years | 123 (1.05%) | n/a | 12 (0.38%) | 79 (0.66%) | 31 (0.64%) | 246 (0.77%) |
| 2 - 4 years | 187 (1.60%) | n/a | 40 (1.28%) | 189 (1.58%) | 66 (1.37%) | 484 (1.52%) |
| 5 - 17 years | 300 (2.56%) | n/a | 122 (3.91%) | 465 (3.90%) | 210 (4.35%) | 1,101 (3.47%) |
| 18 - 49 years | 2,612 (22.28%) | 25 (16.13%) | 760 (24.37%) | 2,586 (21.68%) | 1,078 (22.33%) | 7,061 (22.24%) |
| 50 - 64 years | 2,934 (25.03%) | 43 (27.74%) | 585 (18.76%) | 2,448 (20.53%) | 1,176 (24.36%) | 7,186 (22.63%) |
| 65 - 74 years | 2,311 (19.72%) | 28 (18.06%) | 619 (19.85%) | 2,482 (20.81%) | 968 (20.05%) | 6,408 (20.18%) |
| 75 - 84 years | 1,916 (16.35%) | 35 (22.58%) | 599 (19.20%) | 2,320 (19.45%) | 859 (17.79%) | 5,729 (18.04%) |
| 85+ years | 1,129 (9.63%) | 17 (10.97%) | 355 (11.38%) | 1,246 (10.45%) | 400 (8.29%) | 3,147 (9.91%) |
| Sex | | | | | | |
| Female | 6,373 (54.37%) | 91 (58.71%) | 1,797 (57.61%) | 6,727 (56.41%) | 2,636 (54.60%) | 17,624 (55.51%) |
| Male | 5,307 (45.27%) | 63 (40.65%) | 1,316 (42.19%) | 5,165 (43.31%) | 2,172 (44.99%) | 14,023 (44.17%) |
| Unknown | 42 (0.36%) | n/a | n/a | 34 (0.29%) | 20 (0.41%) | 103 (0.32%) |
| Race | | | | | | |
| White | 7,215 (61.55%) | 100 (64.52%) | 2,035 (65.25%) | 7,561 (63.40%) | 2,819 (58.39%) | 19,730 (62.14%) |
| Black or African American | 2,177 (18.57%) | 32 (20.65%) | 525 (16.83%) | 1,910 (16.02%) | 890 (18.43%) | 5,534 (17.43%) |
| Asian | 391 (3.34%) | n/a | 71 (2.28%) | 355 (2.98%) | 151 (3.13%) | 971 (3.06%) |
| Native Hawaiian or Other Pacific Islander | 16 (0.14%) | n/a | 10 (0.32%) | 25 (0.21%) | 11 (0.23%) | 63 (0.20%) |
| American Indian or Alaska Native | 45 (0.38%) | n/a | 17 (0.55%) | 73 (0.61%) | 16 (0.33%) | 151 (0.48%) |

| | | | | | | |
|---------------------------------------|----------------|--------------|----------------|----------------|----------------|-----------------|
| Other Race | 1,241 (10.59%) | n/a | 286 (9.17%) | 1,207 (10.12%) | 588 (12.18%) | 3,331 (10.49%) |
| Declined to answer | 48 (0.41%) | n/a | 10 (0.32%) | 56 (0.47%) | 26 (0.54%) | 141 (0.44%) |
| Unknown | 589 (5.02%) | n/a | 165 (5.29%) | 739 (6.20%) | 327 (6.77%) | 1,829 (5.76%) |
| Ethnicity | | | | | | |
| Hispanic or Latino | 1,395 (11.90%) | 16 (10.32%) | 395 (12.66%) | 1,669 (13.99%) | 794 (16.45%) | 4,269 (13.45%) |
| Not Hispanic or Latino | 9,256 (78.96%) | 125 (80.65%) | 2,538 (81.37%) | 9,560 (80.16%) | 3,725 (77.15%) | 25,204 (79.38%) |
| Declined to answer | 53 (0.45%) | n/a | 10 (0.32%) | 55 (0.46%) | 23 (0.48%) | 142 (0.45%) |
| Unknown | 1,018 (8.68%) | 13 (8.39%) | 176 (5.64%) | 642 (5.38%) | 286 (5.92%) | 2,135 (6.72%) |
| Comorbidity | | | | | | |
| Asthma | 1,484 (12.66%) | 14 (9.03%) | 481 (15.42%) | 1,769 (14.83%) | 728 (15.08%) | 4,476 (14.10%) |
| Chronic Lung Disease | 885 (7.55%) | n/a | 259 (8.30%) | 1,040 (8.72%) | 383 (7.93%) | 2,575 (8.11%) |
| Chronic Obstructive Pulmonary Disease | 2,113 (18.03%) | 19 (12.26%) | 639 (20.49%) | 2,329 (19.53%) | 847 (17.54%) | 5,947 (18.73%) |

Hospitalization rate over time

The rate of influenza-associated hospitalization is shown in Figure 5. Figure 6 shows seasonal trends.

Figure 5: Rate of weekly influenza-associated hospitalizations compared to all hospital admissions since October 2019





Figure 6: Rate of weekly influenza-associated hospitalizations compared to all hospital admissions by season



Human metapneumovirus (HMPV)

Our HMPV study population consists of 8,783 hospitalizations of 7,486 unique patients (Table 4).

Table 4: HMPV patient characteristics by season.

| | 2019/2020 | 2020/2021 | 2021/2022 | 2022/2023 | 2023/2024 | Overall |
|---|-----------------|---------------|-----------------|-----------------|---------------|-----------------|
| N | 1,928 (100.00%) | 126 (100.00%) | 1,791 (100.00%) | 3,374 (100.00%) | 267 (100.00%) | 7,486 (100.00%) |
| Age Group | | | | | | |
| < 6 months | 44 (2.28%) | 11 (8.73%) | 59 (3.29%) | 140 (4.15%) | 11 (4.12%) | 265 (3.54%) |
| 6 - <12 months | 62 (3.22%) | n/a | 84 (4.69%) | 113 (3.35%) | 13 (4.87%) | 278 (3.71%) |
| 1 - <2 years | 64 (3.32%) | 20 (15.87%) | 134 (7.48%) | 142 (4.21%) | 13 (4.87%) | 373 (4.98%) |
| 2 - 4 years | 70 (3.63%) | 20 (15.87%) | 205 (11.45%) | 243 (7.20%) | 16 (5.99%) | 554 (7.40%) |
| 5 - 17 years | 48 (2.49%) | n/a | 99 (5.53%) | 162 (4.80%) | 14 (5.24%) | 331 (4.42%) |
| 18 - 49 years | 227 (11.77%) | 15 (11.90%) | 198 (11.06%) | 348 (10.31%) | 42 (15.73%) | 830 (11.09%) |
| 50 - 64 years | 377 (19.55%) | 12 (9.52%) | 292 (16.30%) | 553 (16.39%) | 44 (16.48%) | 1,278 (17.07%) |
| 65 - 74 years | 378 (19.61%) | 11 (8.73%) | 282 (15.75%) | 624 (18.49%) | 47 (17.60%) | 1,342 (17.93%) |
| 75 - 84 years | 399 (20.70%) | 15 (11.90%) | 279 (15.58%) | 635 (18.82%) | 30 (11.24%) | 1,358 (18.14%) |
| 85+ years | 259 (13.43%) | n/a | 159 (8.88%) | 414 (12.27%) | 37 (13.86%) | 877 (11.72%) |
| Sex | | | | | | |
| Female | 1,107 (57.42%) | 62 (49.21%) | 1,034 (57.73%) | 1,972 (58.45%) | 157 (58.80%) | 4,332 (57.87%) |
| Male | 817 (42.38%) | 64 (50.79%) | 754 (42.10%) | 1,398 (41.43%) | 110 (41.20%) | 3,143 (41.99%) |
| Unknown | n/a | n/a | n/a | n/a | n/a | 11 (0.15%) |
| Race | | | | | | |
| White | 1,348 (69.92%) | 55 (43.65%) | 1,107 (61.81%) | 2,105 (62.39%) | 155 (58.05%) | 4,770 (63.72%) |
| Black or African American | 203 (10.53%) | 18 (14.29%) | 213 (11.89%) | 338 (10.02%) | 34 (12.73%) | 806 (10.77%) |
| Asian | 57 (2.96%) | n/a | 61 (3.41%) | 147 (4.36%) | 12 (4.49%) | 281 (3.75%) |
| Native Hawaiian or Other Pacific Islander | n/a | n/a | n/a | n/a | n/a | 14 (0.19%) |
| American Indian or Alaska Native | 12 (0.62%) | n/a | n/a | 15 (0.44%) | n/a | 36 (0.48%) |
| Other Race | 197 (10.22%) | 43 (34.13%) | 251 (14.01%) | 454 (13.46%) | 40 (14.98%) | 985 (13.16%) |
| Declined to answer | n/a | n/a | 14 (0.78%) | 20 (0.59%) | n/a | 45 (0.60%) |
| Unknown | 98 (5.08%) | n/a | 131 (7.31%) | 293 (8.68%) | 15 (5.62%) | 549 (7.33%) |
| Ethnicity | | | | | | |
| Hispanic or Latino | 222 (11.51%) | 40 (31.75%) | 278 (15.52%) | 557 (16.51%) | 48 (17.98%) | 1,145 (15.30%) |
| Not Hispanic or Latino | 1,560 (80.91%) | 81 (64.29%) | 1,386 (77.39%) | 2,614 (77.47%) | 202 (75.66%) | 5,843 (78.05%) |
| Declined to answer | n/a | n/a | n/a | 17 (0.50%) | n/a | 33 (0.44%) |
| Unknown | 141 (7.31%) | n/a | 119 (6.64%) | 186 (5.51%) | 15 (5.62%) | 465 (6.21%) |
| Comorbidity | | | | | | |
| Asthma | 290 (15.04%) | 15 (11.90%) | 266 (14.85%) | 504 (14.94%) | 52 (19.48%) | 1,127 (15.05%) |
| Chronic Lung Disease | 230 (11.93%) | n/a | 180 (10.05%) | 285 (8.45%) | 23 (8.61%) | 725 (9.68%) |
| Chronic Obstructive Pulmonary Disease | 418 (21.68%) | n/a | 310 (17.31%) | 563 (16.69%) | 32 (11.99%) | 1,331 (17.78%) |

Hospitalization rate over time

The rate of HMPV-associated hospitalization is shown in Figure 7. Figure 8 shows seasonal trends.

Figure 7: Rate of weekly HMPV-associated hospitalizations compared to all hospital admissions since October 2019





Figure 8: Rate of weekly HMPV-associated hospitalizations compared to all hospital admissions by season



Parainfluenza virus

Our parainfluenza virus study population consists of 8,534 hospitalizations of 6,994 unique patients (Table 5).

Table 5: Parainfluenza virus patient characteristics by season.

| | 2019/2020 | 2020/2021 | 2021/2022 | 2022/2023 | 2023/2024 | Overall |
|----------------|---------------|---------------|-----------------|-----------------|---------------|-----------------|
| N | 925 (100.00%) | 882 (100.00%) | 1,589 (100.00%) | 3,054 (100.00%) | 544 (100.00%) | 6,994 (100.00%) |
| Age Group | | | | | | |
| < 6 months | 41 (4.43%) | 48 (5.44%) | 79 (4.97%) | 153 (5.01%) | 35 (6.43%) | 356 (5.09%) |
| 6 - <12 months | 22 (2.38%) | 33 (3.74%) | 64 (4.03%) | 115 (3.77%) | 17 (3.12%) | 251 (3.59%) |
| 1 - <2 years | 36 (3.89%) | 64 (7.26%) | 83 (5.22%) | 135 (4.42%) | 34 (6.25%) | 352 (5.03%) |
| 2 - 4 years | 43 (4.65%) | 77 (8.73%) | 138 (8.68%) | 211 (6.91%) | 43 (7.90%) | 512 (7.32%) |
| 5 - 17 years | 46 (4.97%) | 61 (6.92%) | 91 (5.73%) | 175 (5.73%) | 45 (8.27%) | 418 (5.98%) |
| 18 - 49 years | 98 (10.59%) | 128 (14.51%) | 203 (12.78%) | 363 (11.89%) | 85 (15.62%) | 877 (12.54%) |
| 50 - 64 years | 185 (20.00%) | 151 (17.12%) | 273 (17.18%) | 506 (16.57%) | 73 (13.42%) | 1,188 (16.99%) |
| 65 - 74 years | 169 (18.27%) | 136 (15.42%) | 278 (17.50%) | 488 (15.98%) | 80 (14.71%) | 1,151 (16.46%) |
| 75 - 84 years | 165 (17.84%) | 113 (12.81%) | 223 (14.03%) | 548 (17.94%) | 78 (14.34%) | 1,127 (16.11%) |
| 85+ years | 120 (12.97%) | 71 (8.05%) | 157 (9.88%) | 360 (11.79%) | 54 (9.93%) | 762 (10.90%) |

| Sex | | | | | | |
|---|--------------|--------------|----------------|----------------|--------------|----------------|
| Female | 501 (54.16%) | 457 (51.81%) | 872 (54.88%) | 1,632 (53.44%) | 311 (57.17%) | 3,773 (53.95%) |
| Male | 417 (45.08%) | 423 (47.96%) | 714 (44.93%) | 1,416 (46.37%) | 231 (42.46%) | 3,201 (45.77%) |
| Unknown | n/a | n/a | n/a | n/a | n/a | 19 (0.27%) |
| Race | | | | | | |
| White | 620 (67.03%) | 527 (59.75%) | 947 (59.60%) | 1,835 (60.09%) | 281 (51.65%) | 4,210 (60.19%) |
| Black or African American | 106 (11.46%) | 123 (13.95%) | 197 (12.40%) | 365 (11.95%) | 75 (13.79%) | 866 (12.38%) |
| Asian | 45 (4.86%) | 37 (4.20%) | 83 (5.22%) | 152 (4.98%) | 27 (4.96%) | 344 (4.92%) |
| Native Hawaiian or Other Pacific Islander | n/a | n/a | n/a | n/a | n/a | 11 (0.16%) |
| American Indian or Alaska Native | n/a | n/a | n/a | 17 (0.56%) | n/a | 35 (0.50%) |
| Other Race | 95 (10.27%) | 122 (13.83%) | 205 (12.90%) | 427 (13.98%) | 96 (17.65%) | 945 (13.51%) |
| Declined to answer | n/a | n/a | 12 (0.76%) | 18 (0.59%) | n/a | 38 (0.54%) |
| Unknown | 50 (5.41%) | 63 (7.14%) | 136 (8.56%) | 238 (7.79%) | 58 (10.66%) | 545 (7.79%) |
| Ethnicity | | | | | | |
| Hispanic or Latino | 83 (8.97%) | 126 (14.29%) | 205 (12.90%) | 491 (16.08%) | 109 (20.04%) | 1,014 (14.50%) |
| Not Hispanic or Latino | 752 (81.30%) | 670 (75.96%) | 1,268 (79.80%) | 2,367 (77.50%) | 394 (72.43%) | 5,451 (77.94%) |
| Declined to answer | n/a | n/a | 10 (0.63%) | 18 (0.59%) | n/a | 31 (0.44%) |
| Unknown | 88 (9.51%) | 86 (9.75%) | 106 (6.67%) | 178 (5.83%) | 40 (7.35%) | 498 (7.12%) |
| Comorbidity | | | | | | |
| Asthma | 150 (16.22%) | 112 (12.70%) | 241 (15.17%) | 455 (14.90%) | 86 (15.81%) | 1,044 (14.93%) |
| Chronic Lung Disease | 117 (12.65%) | 64 (7.26%) | 167 (10.51%) | 276 (9.04%) | 39 (7.17%) | 663 (9.48%) |
| Chronic Obstructive Pulmonary Disease | 201 (21.73%) | 148 (16.78%) | 313 (19.70%) | 563 (18.43%) | 92 (16.91%) | 1,317 (18.83%) |


Hospitalization rate over time

The rate of parainfluenza virus-associated hospitalization is shown in Figure 9. Figure 10 shows seasonal trends.

Figure 9: Rate of weekly parainfluenza virus-associated hospitalizations compared to all hospital admissions since October 2019



Figure 10: Rate of weekly parainfluenza virus-associated hospitalizations compared to all hospital admissions by season



Respiratory syncytial virus (RSV)

Our RSV study population consists of 21,540 hospitalizations of 16,835 unique patients (Table 6).

Table 6: RSV patient characteristics by season.

| | 2019/2020 | 2020/2021 | 2021/2022 | 2022/2023 | 2023/2024 | Overall |
|---------------------------|-----------------|-----------------|-----------------|-----------------|-----------------|------------------|
| N | 3,911 (100.00%) | 1,429 (100.00%) | 2,989 (100.00%) | 5,095 (100.00%) | 3,411 (100.00%) | 16,835 (100.00%) |
| Age Group | | | | | | |
| < 6 months | 717 (18.33%) | 393 (27.50%) | 594 (19.87%) | 972 (19.08%) | 547 (16.04%) | 3,223 (19.14%) |
| 6 - <12 months | 272 (6.95%) | 113 (7.91%) | 204 (6.83%) | 338 (6.63%) | 186 (5.45%) | 1,113 (6.61%) |
| 1 - <2 years | 273 (6.98%) | 152 (10.64%) | 263 (8.80%) | 442 (8.68%) | 217 (6.36%) | 1,347 (8.00%) |
| 2 - 4 years | 268 (6.85%) | 120 (8.40%) | 266 (8.90%) | 470 (9.22%) | 224 (6.57%) | 1,348 (8.01%) |
| 5 - 17 years | 62 (1.59%) | 32 (2.24%) | 97 (3.25%) | 172 (3.38%) | 100 (2.93%) | 463 (2.75%) |
| 18 - 49 years | 217 (5.55%) | 131 (9.17%) | 266 (8.90%) | 384 (7.54%) | 282 (8.27%) | 1,280 (7.60%) |
| 50 - 64 years | 490 (12.53%) | 155 (10.85%) | 359 (12.01%) | 550 (10.79%) | 470 (13.78%) | 2,024 (12.02%) |
| 65 - 74 years | 566 (14.47%) | 145 (10.15%) | 357 (11.94%) | 665 (13.05%) | 522 (15.30%) | 2,255 (13.39%) |
| 75 - 84 years | 613 (15.67%) | 123 (8.61%) | 359 (12.01%) | 679 (13.33%) | 478 (14.01%) | 2,252 (13.38%) |
| 85+ years | 433 (11.07%) | 65 (4.55%) | 224 (7.49%) | 423 (8.30%) | 385 (11.29%) | 1,530 (9.09%) |
| Sex | | | | | | |
| Female | 2,150 (54.97%) | 784 (54.86%) | 1,535 (51.35%) | 2,712 (53.23%) | 1,926 (56.46%) | 9,107 (54.10%) |
| Male | 1,747 (44.67%) | 641 (44.86%) | 1,450 (48.51%) | 2,361 (46.34%) | 1,475 (43.24%) | 7,674 (45.58%) |
| Unknown | 14 (0.36%) | n/a | n/a | 22 (0.43%) | 10 (0.29%) | 54 (0.32%) |
| Race | | | | | | |
| White | 2,410 (61.62%) | 765 (53.53%) | 1,803 (60.32%) | 3,037 (59.61%) | 2,101 (61.59%) | 10,116 (60.09%) |
| Black or African American | 499 (12.76%) | 284 (19.87%) | 386 (12.91%) | 609 (11.95%) | 451 (13.22%) | 2,229 (13.24%) |

| | | | | | | |
|---|----------------|----------------|----------------|----------------|----------------|-----------------|
| Asian | 136 (3.48%) | 46 (3.22%) | 123 (4.12%) | 261 (5.12%) | 121 (3.55%) | 687 (4.08%) |
| Native Hawaiian or Other Pacific Islander | n/a | n/a | n/a | 13 (0.26%) | n/a | 36 (0.21%) |
| American Indian or Alaska Native | 17 (0.43%) | n/a | 20 (0.67%) | 22 (0.43%) | 16 (0.47%) | 81 (0.48%) |
| Other Race | 600 (15.34%) | 251 (17.56%) | 428 (14.32%) | 722 (14.17%) | 432 (12.66%) | 2,433 (14.45%) |
| Declined to answer | n/a | n/a | 16 (0.54%) | 32 (0.63%) | 25 (0.73%) | 84 (0.50%) |
| Unknown | 233 (5.96%) | 72 (5.04%) | 204 (6.83%) | 399 (7.83%) | 261 (7.65%) | 1,169 (6.94%) |
| Ethnicity | | | | | | |
| Hispanic or Latino | 652 (16.67%) | 286 (20.01%) | 513 (17.16%) | 919 (18.04%) | 585 (17.15%) | 2,955 (17.55%) |
| Not Hispanic or Latino | 2,930 (74.92%) | 1,034 (72.36%) | 2,286 (76.48%) | 3,817 (74.92%) | 2,586 (75.81%) | 12,653 (75.16%) |
| Declined to answer | 11 (0.28%) | n/a | 15 (0.50%) | 35 (0.69%) | 24 (0.70%) | 89 (0.53%) |
| Unknown | 318 (8.13%) | 105 (7.35%) | 175 (5.85%) | 324 (6.36%) | 216 (6.33%) | 1,138 (6.76%) |
| Comorbidity | | | | | | |
| Asthma | 475 (12.15%) | 123 (8.61%) | 338 (11.31%) | 654 (12.84%) | 432 (12.66%) | 2,022 (12.01%) |
| Chronic Lung Disease | 288 (7.36%) | 67 (4.69%) | 182 (6.09%) | 342 (6.71%) | 261 (7.65%) | 1,140 (6.77%) |
| Chronic Obstructive Pulmonary Disease | 730 (18.67%) | 143 (10.01%) | 422 (14.12%) | 803 (15.76%) | 524 (15.36%) | 2,622 (15.57%) |

Hospitalization rate over time

The rate of RSV-associated hospitalization is shown in Figure 11. Figure 12 shows seasonal trends.

Figure 11: Rate of weekly RSV-associated hospitalizations compared to all hospital admissions since October 2019





Figure 12: Rate of weekly RSV-associated hospitalizations compared to all hospital admissions by season



Rhinovirus

Our rhinovirus study population consists of 39,495 hospitalizations of 32,246 unique patients (Table 7).

Table 7: Rhinovirus patient characteristics by season.

| | 2019/2020 | 2020/2021 | 2021/2022 | 2022/2023 | 2023/2024 | Overall |
|---|-----------------|-----------------|-----------------|------------------|-----------------|------------------|
| N | 5,902 (100.00%) | 4,569 (100.00%) | 6,585 (100.00%) | 11,478 (100.00%) | 3,712 (100.00%) | 32,246 (100.00%) |
| Age Group | | | | | | |
| < 6 months | 340 (5.76%) | 297 (6.50%) | 510 (7.74%) | 714 (6.22%) | 243 (6.55%) | 2,104 (6.52%) |
| 6 - <12 months | 171 (2.90%) | 194 (4.25%) | 311 (4.72%) | 358 (3.12%) | 142 (3.83%) | 1,176 (3.65%) |
| 1 - <2 years | 258 (4.37%) | 339 (7.42%) | 607 (9.22%) | 667 (5.81%) | 212 (5.71%) | 2,083 (6.46%) |
| 2 - 4 years | 369 (6.25%) | 457 (10.00%) | 942 (14.31%) | 1,106 (9.64%) | 280 (7.54%) | 3,154 (9.78%) |
| 5 - 17 years | 387 (6.56%) | 563 (12.32%) | 920 (13.97%) | 1,452 (12.65%) | 389 (10.48%) | 3,711 (11.51%) |
| 18 - 49 years | 1,002 (16.98%) | 957 (20.95%) | 913 (13.86%) | 1,864 (16.24%) | 635 (17.11%) | 5,371 (16.66%) |
| 50 - 64 years | 1,091 (18.49%) | 650 (14.23%) | 770 (11.69%) | 1,572 (13.70%) | 527 (14.20%) | 4,610 (14.30%) |
| 65 - 74 years | 925 (15.67%) | 496 (10.86%) | 709 (10.77%) | 1,534 (13.36%) | 531 (14.30%) | 4,195 (13.01%) |
| 75 - 84 years | 793 (13.44%) | 382 (8.36%) | 564 (8.56%) | 1,324 (11.54%) | 468 (12.61%) | 3,531 (10.95%) |
| 85+ years | 566 (9.59%) | 234 (5.12%) | 339 (5.15%) | 887 (7.73%) | 285 (7.68%) | 2,311 (7.17%) |
| Sex | | | | | | |
| Female | 2,958 (50.12%) | 2,291 (50.14%) | 3,130 (47.53%) | 5,764 (50.22%) | 1,854 (49.95%) | 15,997 (49.61%) |
| Male | 2,926 (49.58%) | 2,259 (49.44%) | 3,446 (52.33%) | 5,686 (49.54%) | 1,849 (49.81%) | 16,166 (50.13%) |
| Unknown | 18 (0.30%) | 19 (0.42%) | n/a | 28 (0.24%) | n/a | 83 (0.26%) |
| Race | | | | | | |
| White | 3,669 (62.17%) | 2,513 (55.00%) | 3,500 (53.15%) | 6,258 (54.52%) | 2,036 (54.85%) | 17,976 (55.75%) |
| Black or African American | 840 (14.23%) | 760 (16.63%) | 1,065 (16.17%) | 1,736 (15.12%) | 583 (15.71%) | 4,984 (15.46%) |
| Asian | 237 (4.02%) | 188 (4.11%) | 337 (5.12%) | 551 (4.80%) | 150 (4.04%) | 1,463 (4.54%) |
| Native Hawaiian or Other Pacific Islander | 14 (0.24%) | n/a | 11 (0.17%) | 20 (0.17%) | n/a | 58 (0.18%) |
| American Indian or Alaska Native | 37 (0.63%) | 27 (0.59%) | 25 (0.38%) | 77 (0.67%) | 14 (0.38%) | 180 (0.56%) |
| Other Race | 716 (12.13%) | 787 (17.22%) | 1,128 (17.13%) | 1,803 (15.71%) | 588 (15.84%) | 5,022 (15.57%) |
| Declined to answer | 23 (0.39%) | 14 (0.31%) | 48 (0.73%) | 71 (0.62%) | 45 (1.21%) | 201 (0.62%) |
| Unknown | 366 (6.20%) | 274 (6.00%) | 471 (7.15%) | 962 (8.38%) | 289 (7.79%) | 2,362 (7.32%) |
| Ethnicity | | | | | | |
| Hispanic or Latino | 734 (12.44%) | 717 (15.69%) | 1,125 (17.08%) | 2,103 (18.32%) | 647 (17.43%) | 5,326 (16.52%) |
| Not Hispanic or Latino | 4,679 (79.28%) | 3,522 (77.08%) | 4,987 (75.73%) | 8,622 (75.12%) | 2,824 (76.08%) | 24,634 (76.39%) |
| Declined to answer | 20 (0.34%) | 17 (0.37%) | 47 (0.71%) | 60 (0.52%) | 27 (0.73%) | 171 (0.53%) |
| Unknown | 469 (7.95%) | 313 (6.85%) | 426 (6.47%) | 693 (6.04%) | 214 (5.77%) | 2,115 (6.56%) |

| Comorbidity | | | | | | |
|---------------------------------------|----------------|--------------|----------------|----------------|--------------|----------------|
| Asthma | 1,041 (17.64%) | 750 (16.41%) | 1,077 (16.36%) | 1,907 (16.61%) | 585 (15.76%) | 5,360 (16.62%) |
| Chronic Lung Disease | 656 (11.11%) | 344 (7.53%) | 425 (6.45%) | 800 (6.97%) | 259 (6.98%) | 2,484 (7.70%) |
| Chronic Obstructive Pulmonary Disease | 1,210 (20.50%) | 621 (13.59%) | 737 (11.19%) | 1,575 (13.72%) | 502 (13.52%) | 4,645 (14.40%) |


Hospitalization rate over time

The rate of rhinovirus-associated hospitalization is shown in Figure 13. Figure 14 shows seasonal trends.

Figure 13: Rate of weekly rhinovirus-associated hospitalizations compared to all hospital admissions since October 2019



Figure 14: Rate of weekly rhinovirus-associated hospitalizations compared to all hospital admissions by season



Infants and children (age 0-4)

Our infants and children study population consists of 29,514 hospitalizations of 23,355 unique patients (Table 8).

Table 8: Infants and children patient characteristics by season.

| | 2019/2020 | 2020/2021 | 2021/2022 | 2022/2023 | 2023/2024 | Overall |
|---|-----------------|-----------------|-----------------|-----------------|-----------------|------------------|
| N | 3,705 (100.00%) | 3,297 (100.00%) | 6,375 (100.00%) | 7,457 (100.00%) | 2,521 (100.00%) | 23,355 (100.00%) |
| Age Group | | | | | | |
| < 6 months | 1,352 (36.49%) | 1,299 (39.40%) | 2,196 (34.45%) | 2,391 (32.06%) | 934 (37.05%) | 8,172 (34.99%) |
| 6 - <12 months | 622 (16.79%) | 435 (13.19%) | 888 (13.93%) | 1,125 (15.09%) | 402 (15.95%) | 3,472 (14.87%) |
| 1 - <2 years | 771 (20.81%) | 716 (21.72%) | 1,355 (21.25%) | 1,577 (21.15%) | 536 (21.26%) | 4,955 (21.22%) |
| 2 - 4 years | 960 (25.91%) | 847 (25.69%) | 1,936 (30.37%) | 2,364 (31.70%) | 649 (25.74%) | 6,756 (28.93%) |
| Sex | | | | | | |
| Female | 1,624 (43.83%) | 1,431 (43.40%) | 2,678 (42.01%) | 3,198 (42.89%) | 1,110 (44.03%) | 10,041 (42.99%) |
| Male | 2,070 (55.87%) | 1,856 (56.29%) | 3,691 (57.90%) | 4,241 (56.87%) | 1,410 (55.93%) | 13,268 (56.81%) |
| Unknown | 11 (0.30%) | 10 (0.30%) | n/a | 18 (0.24%) | n/a | 46 (0.20%) |
| Race | | | | | | |
| White | 1,600 (43.18%) | 1,468 (44.53%) | 2,887 (45.29%) | 3,242 (43.48%) | 1,140 (45.22%) | 10,337 (44.26%) |
| Black or African American | 629 (16.98%) | 644 (19.53%) | 1,094 (17.16%) | 1,183 (15.86%) | 414 (16.42%) | 3,964 (16.97%) |
| Asian | 209 (5.64%) | 149 (4.52%) | 349 (5.47%) | 537 (7.20%) | 131 (5.20%) | 1,375 (5.89%) |
| Native Hawaiian or Other Pacific Islander | 16 (0.43%) | n/a | 15 (0.24%) | 24 (0.32%) | n/a | 69 (0.30%) |
| American Indian or Alaska Native | 21 (0.57%) | 10 (0.30%) | 28 (0.44%) | 51 (0.68%) | 12 (0.48%) | 122 (0.52%) |
| Other Race | 1,043 (28.15%) | 867 (26.30%) | 1,495 (23.45%) | 1,730 (23.20%) | 547 (21.70%) | 5,682 (24.33%) |
| Declined to answer | 12 (0.32%) | 10 (0.30%) | 47 (0.74%) | 48 (0.64%) | 36 (1.43%) | 153 (0.66%) |
| Unknown | 175 (4.72%) | 134 (4.06%) | 460 (7.22%) | 642 (8.61%) | 233 (9.24%) | 1,653 (7.08%) |
| Ethnicity | | | | | | |
| Hispanic or Latino | 1,099 (29.66%) | 844 (25.60%) | 1,538 (24.13%) | 2,043 (27.40%) | 661 (26.22%) | 6,185 (26.48%) |
| Not Hispanic or Latino | 2,343 (63.24%) | 2,201 (66.76%) | 4,380 (68.71%) | 4,823 (64.68%) | 1,646 (65.29%) | 15,393 (65.91%) |
| Declined to answer | n/a | 10 (0.30%) | 32 (0.50%) | 38 (0.51%) | 20 (0.79%) | 109 (0.47%) |
| Unknown | 254 (6.86%) | 242 (7.34%) | 425 (6.67%) | 553 (7.42%) | 194 (7.70%) | 1,668 (7.14%) |
| Virus | | | | | | |
| COVID | 135 (3.64%) | 950 (28.81%) | 1,753 (27.50%) | 759 (10.18%) | 151 (5.99%) | 3,748 (16.05%) |
| HMPV | 240 (6.48%) | 57 (1.73%) | 482 (7.56%) | 638 (8.56%) | 53 (2.10%) | 1,470 (6.29%) |
| RSV | 1,530 (41.30%) | 778 (23.60%) | 1,327 (20.82%) | 2,222 (29.80%) | 1,174 (46.57%) | 7,031 (30.10%) |
| influenza | 520 (14.04%) | n/a | 79 (1.24%) | 379 (5.08%) | 137 (5.43%) | 1,118 (4.79%) |
| parainfluenza virus | 142 (3.83%) | 222 (6.73%) | 364 (5.71%) | 614 (8.23%) | 129 (5.12%) | 1,471 (6.30%) |
| rhinovirus | 1,138 (30.72%) | 1,287 (39.04%) | 2,370 (37.18%) | 2,845 (38.15%) | 877 (34.79%) | 8,517 (36.47%) |
| Comorbidity | | | | | | |
| Asthma | 229 (6.18%) | 176 (5.34%) | 341 (5.35%) | 455 (6.10%) | 142 (5.63%) | 1,343 (5.75%) |
| Chronic Lung Disease | 33 (0.89%) | 16 (0.49%) | 27 (0.42%) | 47 (0.63%) | 13 (0.52%) | 136 (0.58%) |
| Chronic Obstructive Pulmonary Disease | n/a | n/a | n/a | 10 (0.13%) | n/a | 21 (0.09%) |


Hospitalization rate over time

The rate of respiratory virus-associated hospitalizations compared to all hospitalizations for infants and children under five is shown in Figure 15. Figure 16 shows the same data stacked to represent the combined impact of the viruses.

Figure 15: Rate of weekly respiratory virus-associated hospitalizations compared to all hospital admissions since October 2019 for infants and children under five



Figure 16: Cumulative rate of weekly respiratory virus-associated hospitalizations compared to all hospital admissions since October 2019 for infants and children under five



Older adults (age 65 and over)

Our older adults study population consists of 244,965 hospitalizations of 230,770 unique patients (Table 9).

Table 9: Older adults patient characteristics by season.

| | 2019/2020 | 2020/2021 | 2021/2022 | 2022/2023 | 2023/2024 | Overall |
|---------------|---------------------|---------------------|---------------------|---------------------|---------------------|----------------------|
| N | 32,388 (100.00%) | 67,390 (100.00%) | 67,464 (100.00%) | 50,051 (100.00%) | 13,477 (100.00%) | 230,770 (100.00%) |
| Age Group | | | | | | |
| 65 - 74 years | 13,960 (43.10%) | 29,868 (44.32%) | 26,560 (39.37%) | 17,094 (34.15%) | 4,563 (33.86%) | 92,045 (39.89%) |
| 75 - 84 years | 11,692 (36.10%) | 24,347 (36.13%) | 25,386 (37.63%) | 19,599 (39.16%) | 5,252 (38.97%) | 86,276 (37.39%) |
| 85+ years | 6,736 (20.80%) | 13,175 (19.55%) | 15,518 (23.00%) | 13,358 (26.69%) | 3,662 (27.17%) | 52,449 (22.73%) |

| Sex | | | | | | |
|---|-----------------|-----------------|-----------------|-----------------|-----------------|------------------|
| Female | 16,592 (51.23%) | 33,774 (50.12%) | 34,560 (51.23%) | 26,646 (53.24%) | 7,203 (53.45%) | 118,775 (51.47%) |
| Male | 15,694 (48.46%) | 33,352 (49.49%) | 32,673 (48.43%) | 23,269 (46.49%) | 6,221 (46.16%) | 111,209 (48.19%) |
| Unknown | 102 (0.31%) | 264 (0.39%) | 228 (0.34%) | 136 (0.27%) | 52 (0.39%) | 782 (0.34%) |
| Race | | | | | | |
| White | 20,154 (62.23%) | 49,109 (72.87%) | 51,197 (75.89%) | 36,955 (73.83%) | 9,901 (73.47%) | 167,316 (72.50%) |
| Black or African American | 5,218 (16.11%) | 7,016 (10.41%) | 6,486 (9.61%) | 4,348 (8.69%) | 1,137 (8.44%) | 24,205 (10.49%) |
| Asian | 1,091 (3.37%) | 1,525 (2.26%) | 1,470 (2.18%) | 1,530 (3.06%) | 400 (2.97%) | 6,016 (2.61%) |
| Native Hawaiian or Other Pacific Islander | 22 (0.07%) | 47 (0.07%) | 49 (0.07%) | 29 (0.06%) | 10 (0.07%) | 157 (0.07%) |
| American Indian or Alaska Native | 67 (0.21%) | 141 (0.21%) | 180 (0.27%) | 190 (0.38%) | 47 (0.35%) | 625 (0.27%) |
| Other Race | 3,535 (10.91%) | 5,444 (8.08%) | 4,291 (6.36%) | 3,485 (6.96%) | 971 (7.20%) | 17,726 (7.68%) |
| Declined to answer | 122 (0.38%) | 214 (0.32%) | 238 (0.35%) | 228 (0.46%) | 64 (0.47%) | 866 (0.38%) |
| Unknown | 2,179 (6.73%) | 3,894 (5.78%) | 3,553 (5.27%) | 3,286 (6.57%) | 947 (7.03%) | 13,859 (6.01%) |
| Ethnicity | | | | | | |
| Hispanic or Latino | 3,154 (9.74%) | 5,769 (8.56%) | 4,803 (7.12%) | 3,936 (7.86%) | 1,084 (8.04%) | 18,746 (8.12%) |
| Not Hispanic or Latino | 24,928 (76.97%) | 54,178 (80.39%) | 57,040 (84.55%) | 42,723 (85.36%) | 11,522 (85.49%) | 190,391 (82.50%) |
| Declined to answer | 144 (0.44%) | 305 (0.45%) | 319 (0.47%) | 259 (0.52%) | 75 (0.56%) | 1,102 (0.48%) |
| Unknown | 4,162 (12.85%) | 7,138 (10.59%) | 5,302 (7.86%) | 3,133 (6.26%) | 796 (5.91%) | 20,531 (8.90%) |
| Virus | | | | | | |
| COVID | 21,646 (66.83%) | 65,511 (97.21%) | 61,961 (91.84%) | 35,422 (70.77%) | 8,255 (61.25%) | 192,795 (83.54%) |
| HMPV | 1,036 (3.20%) | 34 (0.05%) | 720 (1.07%) | 1,673 (3.34%) | 114 (0.85%) | 3,577 (1.55%) |
| RSV | 1,612 (4.98%) | 333 (0.49%) | 940 (1.39%) | 1,767 (3.53%) | 1,385 (10.28%) | 6,037 (2.62%) |
| influenza | 5,356 (16.54%) | 80 (0.12%) | 1,573 (2.33%) | 6,048 (12.08%) | 2,227 (16.52%) | 15,284 (6.62%) |
| parainfluenza virus | 454 (1.40%) | 320 (0.47%) | 658 (0.98%) | 1,396 (2.79%) | 212 (1.57%) | 3,040 (1.32%) |
| rhinovirus | 2,284 (7.05%) | 1,112 (1.65%) | 1,612 (2.39%) | 3,745 (7.48%) | 1,284 (9.53%) | 10,037 (4.35%) |
| Comorbidity | | | | | | |
| Asthma | 2,716 (8.39%) | 4,404 (6.54%) | 5,359 (7.94%) | 4,908 (9.81%) | 1,498 (11.12%) | 18,885 (8.18%) |
| Chronic Lung Disease | 2,323 (7.17%) | 3,959 (5.87%) | 4,532 (6.72%) | 4,158 (8.31%) | 1,297 (9.62%) | 16,269 (7.05%) |
| Chronic Obstructive Pulmonary Disease | 5,745 (17.74%) | 10,324 (15.32%) | 12,774 (18.93%) | 10,608 (21.19%) | 3,073 (22.80%) | 42,524 (18.43%) |

Hospitalization rate over time

The rate of respiratory virus-associated hospitalizations compared to all hospitalizations for adults 65 and over is shown in Figure 17. Figure 18 shows the same data stacked to represent the combined impact of the viruses.

Figure 17: Rate of weekly respiratory virus-associated hospitalizations compared to all hospital admissions since October 2019 for adults 65 years or older





Figure 18: Cumulative rate of weekly respiratory virus-associated hospitalizations compared to all hospital admissions since October 2019 for adults 65 years or older



Discussion and Conclusion

Overall, the rate of hospitalizations associated with respiratory viruses continue to increase through the end of December 2023 (92.8% increase since November 2023). Specifically, COVID- (88.6%), flu- (251.7%), and HMPV- (115.0%) associated hospitalization trends increased. COVID and influenza-associated hospitalizations are at 3.3% and 3.0% of all hospitalizations, respectively. Other viruses are each below 1% of hospitalizations. Nevertheless, at the end of December 2023, respiratory virus-associated hospitalizations accounted for 7.7% of all hospitalizations.

For the population between 0-4 years old, in December 2023, RSV accounted for the most virus-associated hospitalizations, despite decreasing rates since November 2023 (24.7% decrease). COVID- (183.5% increase), influenza- (52.5% increase), and rhino-associated (39.5% increase) hospitalizations are increasing in this population. In this age group 5.1% of all hospitalizations were associated with respiratory viruses in December 2023, a 10.5% increase from November 2023.

In the older adults population (individuals over 65 years of age), there was a 93.7% increase in hospitalizations associated with respiratory viruses; 10.3% of all hospitalizations are associated with a respiratory virus. Influenza-associated

hospitalizations had the largest percent increase between November and December 2023 (267.8%). COVID-associated hospitalizations continue to make up the largest percentage of hospitalizations in this age group (5.3% in December).

Several limitations of our analysis should be noted. All data are preliminary and may change as additional data are obtained. These findings are consistent with data accessed January 15, 2024. These are raw counts and post-stratification methods have not been conducted. This analysis does not include patients hospitalized with a respiratory virus who were not tested or were tested later in their medical care (when laboratory tests results would have returned a negative result). In addition, cohorts with small counts may be suppressed during the de-identification process leading to the appearance of zero patients for a given time period. Moreover, the unknowns in this report either indicate the value was not included in the individual's electronic health record or that it was excluded from the data to protect an individual's identity as a part of Truveta's commitment to privacy (Truveta, 2024).

We will continue to monitor respiratory virus-associated hospitalization overall and for the at-risk populations.

References

Boyce, T. G., Mellen, B. G., Mitchel, E. F., Wright, P. F., & Griffin, M. R. (2000). Rates of hospitalization for respiratory syncytial virus infection among children in Medicaid. *The Journal of Pediatrics*, 137(6), 865-870. <https://doi.org/10.1067/mpd.2000.110531>

Centers for Disease Control and Prevention. (2023a, April 10). Past seasons estimated influenza disease burden. Table Print. <https://www.cdc.gov/flu/about/burden/past-seasons.html>

Centers for Disease Control and Prevention. (2023b, April 4). The National Respiratory and Enteric Virus Surveillance System (NREVSS). Dashboard Print. <https://www.cdc.gov/surveillance/nrevss/index.html>

Centers for Disease Control and Prevention. (2023c, April 10). Influenza Hospitalization Surveillance Network (FluSurv-NET). Interactive Dashboard Print. <https://www.cdc.gov/flu/weekly/influenza-hospitalization-surveillance.htm>

Centers for Disease Control and Prevention. (2023d, April 10). RSV-NET Interactive Dashboard Print. <https://www.cdc.gov/rsv/research/rsv-net/dashboard.html>

Committee on Infectious Diseases and Bronchiolitis Guidelines Committee, Brady, M. T., Byington, C. L., Davies, H. D., Edwards, K. M., Jackson, M. A., Maldonado, Y. A., Murray,

D. L., Orenstein, W. A., Rathore, M. H., Sawyer, M. H., Schutze, G. E., Willoughby, R. E., Zaoutis, T. E., Ralston, S. L., Lieberthal, A. S., Meissner, H. C., Alverson, B. K., Baley, J. E., ... Hernández-Cancio, S. (2014). Updated Guidance for Palivizumab Prophylaxis Among Infants and Young Children at Increased Risk of Hospitalization for Respiratory Syncytial Virus Infection. *Pediatrics*, 134(2), e620-e638.

<https://doi.org/10.1542/peds.2014-1666>

Christopher A Czaja, Lisa Miller, Nisha Alden, Heidi L Wald, Charisse Nitura Cummings, Melissa A Rolfes, Evan J Anderson, Nancy M Bennett, Laurie M Billing, Shua J Chai, Seth Eckel, Robert Mansmann, Melissa McMahan, Maya L Monroe, Alison Muse, Ilene Risk, William Schaffner, Ann R Thomas, Kimberly Yousey-Hindes, Shikha Garg, Rachel K Herlihy, Age-Related Differences in Hospitalization Rates, Clinical Presentation, and Outcomes Among Older Adults Hospitalized With Influenza—U.S. Influenza Hospitalization Surveillance Network (FluSurv-NET), *Open Forum Infectious Diseases*, Volume 6, Issue 7, July 2019, ofz225, <https://doi.org/10.1093/ofid/ofz225>

Lee, N., Lui, G. C. Y., Wong, K. T., Li, T. C. M., Tse, E. C. M., Chan, J. Y. C., Yu, J., Wong, S. S. M., Choi, K. W., Wong, R. Y. K., Ngai, K. L. K., Hui, D. S. C., & Chan, P. K. S. (2013). High Morbidity and Mortality in Adults Hospitalized for Respiratory Syncytial Virus Infections. *Clinical Infectious Diseases*, 57(8), 1069–1077. <https://doi.org/10.1093/cid/cit471>

Pastula, S. T., Hackett, J., Coalson, J., Jiang, X., Villafana, T., Ambrose, C., & Fryzek, J. (2017). Hospitalizations for Respiratory Syncytial Virus Among Adults in the United States, 1997–2012. *Open Forum Infectious Diseases*, 4(1), ofw270.

<https://doi.org/10.1093/ofid/ofw270>

Shi, T., McAllister, D. A., O'Brien, K. L., Simoes, E. A. F., Madhi, S. A., Gessner, B. D., Polack, F. P., Balsells, E., Acacio, S., Aguayo, C., Alassani, I., Ali, A., Antonio, M., Awasthi, S., Awori, J. O., Azziz-Baumgartner, E., Baggett, H. C., Baillie, V. L., Balmaseda, A., ... Nair, H. (2017). Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in young children in 2015: A systematic review and modelling study. *The Lancet*, 390(10098), 946–958.

[https://doi.org/10.1016/S0140-6736\(17\)30938-8](https://doi.org/10.1016/S0140-6736(17)30938-8)

Smits PD, Gratzl S, Simonov M, Nachimuthu SK, Goodwin Cartwright BM, Wang MD, Baker C, Rodriguez P, Bogiages M, Althouse BM, Stucky NL. Risk of COVID-19 breakthrough infection and hospitalization in individuals with comorbidities. *Vaccine*. 2023 Apr 6;41(15):2447-2455. <https://doi.org/10.1016/j.vaccine.2023.02.038>. Epub 2023 Feb 16. PMID: 36803895; PMCID: PMC9933320.

Tokars JI, Olsen SJ, Reed C. Seasonal Incidence of Symptomatic Influenza in the United States. Clin Infect Dis. 2018 May 2;66(10):1511-1518.

<https://doi.org/10.1093/cid/cix1060>. PMID: 29206909; PMCID: PMC5934309.

Truveta. (2024). Truveta's Approach to Patient Privacy.

<https://resources.truveta.com/patient-privacy>